1. Cathepsin S as an early biomarker for cardiovascular disease in chronic kidney disease patients.
- Author
-
Sonkar SK, Singh PK, Chandra S, Sonkar GK, Bhosale V, and Sharma S
- Subjects
- Albumins, Biomarkers, Blood Glucose, Calcium, Cathepsins, Creatinine, Electrolytes, Glycated Hemoglobin, Humans, Lipids, Parathyroid Hormone, Risk Factors, Urea, Uric Acid, Vitamin D, Cardiovascular Diseases epidemiology, Renal Insufficiency, Chronic
- Abstract
Introduction: A high incidence of cardiovascular disease (CVD) events and premature mortality is observed in patients with chronic kidney disease (CKD). Thus, new biomarkers that may help predict the development of CVD in early stages of CKD are being investigated along with other traditional risk factors., Objective: To investigate cathepsin S as an early biomarker for CVD in patients with CKD., Methods: A total of 64 patients with CKD were included and classified into 2 groups: CKD patients with established CVD and CKD patients with non-established CVD. All patients were submitted to routine investigations including complete blood count, random blood sugar, glycated hemoglobin (HbA1c), serum electrolytes, urea, creatinine, total protein, total albumin, calcium total, phosphorous, uric acid, vitamin D, parathormone, lipid profile, liver function test, measurement of serum cathepsin S (Cat S), and 2D Echo of the heart., Results: The level of serum Cat S was increased in CKD patients with CVD (p <0.05) as well as in later stages of CKD (p <0.05). CVD was also more common in patients in early stage CKD. In early stages CKD, Cat S and CVD were positively correlated., Conclusion: These findings suggest that serum Cat S might be useful as an early biomarker for CVD in CKD patients.
- Published
- 2022
- Full Text
- View/download PDF